MARCKS effector domain and PKC activation mediate pathological tunneling nanotubes in glioblastoma cells
Background
During glioblastoma (GBM) progression, therapeutic resistance is a major challenge, driven by a complex tumor microenvironment and adaptive defense mechanisms. Tunneling nanotubes (TNTs) have emerged as critical mediators of this resistance, enabling tumor cell survival through metabolic rescue and reprogramming surrounding normal cells into tumor-supportive phenotypes. Specifically, TNT-mediated interactions between brain tumor-initiating cells (BTICs) and normal human astrocytes (NHAs) are crucial. The molecular mediators of this crosstalk, particularly the role of Myristoylated Alanine Rich C-Kinase Substrate (MARCKS), which influences GBM therapeutic resistance and overlaps with relevant signaling pathways, have remained largely unexplored.
Study Design
Researchers investigated the role of MARCKS in TNT formation and functionality between PTEN-null GBM BTICs and NHAs. They utilized a MARCKS phosphorylation site (MPS) peptide derived from the MARCKS effector domain (MED2), along with PKC-targeting drugs. An inducible MARCKS ED U87 model was also employed to further elucidate the involvement of MARCKS phosphorylation and PKC in TNT regulation. The study aimed to identify the molecular mediators underlying TNT-mediated intercellular communication.
Results
The study demonstrated a critical role for the MARCKS effector domain (ED) and PKC activation in regulating the formation and functionality of tunneling nanotubes (TNTs) between PTEN-null glioblastoma brain tumor-initiating cells (BTICs) and normal human astrocytes (NHAs). Using a MARCKS phosphorylation site (MPS) peptide derived from MED2, researchers showed that this peptide, along with PKC-targeting drugs, modulated TNT dynamics. An inducible MARCKS ED U87 model further supported the involvement of MARCKS phosphorylation and PKC in TNT regulation between GBM cells and NHAs. This work specifically elucidated that the MARCKS effector domain and PKC activation are key molecular mediators underlying TNT-mediated intercellular communication, which contributes to GBM progression and therapeutic resistance. This mechanism promotes tumor cell survival and enables the recruitment and reprogramming of surrounding normal cells into tumor-supportive phenotypes.
Key Findings
- MARCKS effector domain (ED) and PKC activation mediate tunneling nanotube (TNT) formation and function.
- TNTs facilitate metabolic rescue and reprogram normal cells into tumor-supportive phenotypes in glioblastoma (GBM).
- A MARCKS phosphorylation site (MPS) peptide derived from MED2 modulates TNT dynamics.
- PKC-targeting drugs influence TNT regulation between GBM cells and astrocytes.
Why It Matters
Identifying MARCKS and PKC as key mediators of TNTs in glioblastoma opens new avenues for therapeutic intervention. Targeting MARCKS or PKC could disrupt the critical intercellular communication that fuels tumor progression and therapeutic resistance in GBM. This research suggests that future GBM treatment strategies might involve compounds that specifically inhibit MARCKS effector domain function or modulate PKC activity to block TNT formation. While still at the in-vitro stage, this mechanistic insight provides a strong rationale for developing novel small molecules or peptides that interfere with this crucial tumor-supportive pathway, potentially enhancing the efficacy of existing chemoradiotherapy.
marcks
glioblastoma
tunneling-nanotubes
pkc
cell-communication
cancer-resistance